Home Tags Novartis

Tag: Novartis

Novartis executive Jay Bradner says that the company is developing drugs that could prevent cancer before patients get it — a forward-thinking approach that other drugmakers aren't taking.

A top Novartis executive says the $225 billion drug giant is planning for a ‘doomsday scenario’ in cancer treatment

Pharma giant Novartis is developing drugs that could prevent cancer before patients get it. One big question: how will we pay for them?

A revolutionary drug that could treat a rare and devastating disease is prohibitively expensive. But one state has a plan to pay for its potential $5 ...

A one-time treatment for a devastating rare disease could be paid for with an installment plan in Massachusetts. That could set a roadmap for the US.
A federal antitrust case brought by 45 states alleges that nearly 20 generic drug companies illegally collaborated to jack up prices for their drugs.

A huge lawsuit accuses nearly 20 big drug companies, a billionaire, and 2 brothers-in-law of cozying up to hike drug prices. Here’s the inside s...

Business Insider is the first to report on the unredacted suit, which alleges frequent, close communications among employees of rival companies about how to increase prices.
A Tilray worker tends to cannabis plants.

Tilray is soaring after announcing a deal with a unit of the Swiss drug giant Novartis to take its medical products global

Tilray rallied 10% Tuesday after saying it has partnered with a unit of Swiss drug giant Novartis to develop its medical cannabis products globally.
A new product from Novartis' Sandoz is set to launch in the first quarter of 2019 and compete directly with Mylan's EpiPen and other products.

Drug giant Novartis is gearing up to release a cheaper EpiPen rival, but one big factor may make competition tricky

The Thursday announcement shows an end in sight for the 17-month saga that has stretched since Symjepi was first approved by U.S. regulators.
Novartis CEO Vas Narasimhan speaks at the Forbes Healthcare Summit in New York.

A big pharma CEO said he was ‘completely blindsided’ by his company’s deal with Trump’s former lawyer

Novartis CEO Vas Narasimhan said he was 'completely blindsided" when the drug company was thrown into the political spotlight over its contract with President Donald Trump's former lawyer.
Novartis CEO Vas Narasimhan

Novartis is going after a $5 billion market with a new treatment for vision loss. That’s a big threat to Regeneron

Novartis' drug brolucizumab just showed that it wasn't any worse than Eylea, a drug from Regeneron, at treating an eye disease.
Novartis CEO Vas Narasimhan

Cancer-therapy provider Endocyte spikes 50% after Novartis agrees to buy it for $2.1 billion

Endocyte, a US cancer-treatment provider, entered into a deal on Thursday to be acquired by Swiss drug maker Novartis. Endocyte shared exploded 50% to $23.48 apiece following the news.
An illustration of a man suffering from a migraine.

Drugmakers are using an unusual tactic to compete in a new class of medication treating the 38 million Americans who have migraines

Until May, there weren't any FDA-approved drugs available for alleviating migraines, though other treatments — including Botox and anti-seizure medications — have been used. Pain relievers can also help treat some of the symptoms of migraines.
A human brain and its millions of small nerves

A new migraine medication that’s changing the way we treat a condition that affects 38 million Americans just got approved

The FDA just approved a new preventative migraine medication made by drug giant Eli Lilly. The drug, Emgality, is the third in a competitive new class of medication going after the 38 million Americans who have migraines.